Literature DB >> 25377565

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Giuseppe Visani1, Pietro Maria Stefani2, Saveria Capria3, Lara Malerba1, Piero Galieni4, Francesco Gaudio5, Giorgina Specchia5, Giovanna Meloni3, Filippo Gherlinzoni2, Roberta Gonella6, Marco Gobbi6, Armando Santoro7, Felicetto Ferrara8, Marco Rocchi9, Enrique M Ocio10, Maria Dolores Caballero10, Federica Loscocco1, Alessandro Isidori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25377565     DOI： 10.1182/blood-2014-08-596668

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

Authors:  S Garciaz; D Coso; J-M Schiano de Collela; F Broussais; A-M Stoppa; T Aurran; C Chabannon; A Helvig; L Xerri; D Blaise; R Bouabdallah
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

Review 2.  Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Authors:  G Damaj; J Cornillon; K Bouabdallah; R Gressin; S Vigouroux; T Gastinne; F Ranchon; H Ghésquières; G Salles; I Yakoub-Agha; E Gyan
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

Review 3.  Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Authors:  Alessandro Isidori; Cristina Clissa; Federica Loscocco; Barbara Guiducci; Sara Barulli; Lara Malerba; Elisa Gabucci; Giuseppe Visani
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

4.  Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

Authors:  L Sellner; A Boumendil; H Finel; S Choquet; G de Rosa; F Falzetti; R Scime; G Kobbe; F Ferrara; A Delmer; H Sayer; S Amorim; R Bouabdallah; J Finke; G Salles; I Yakoub-Agha; E Faber; E Nicolas-Virelizier; L Facchini; D Vallisa; E Zuffa; A Sureda; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-11-16       Impact factor: 5.483

5.  Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.

Authors:  Magalie P Tardy; Lauris Gastaud; Mario Ojeda-Uribe; Annick Boscagli; Salvatore Caruso; Richard Skaf; Jean Gutnecht; Antoine Thyss; Frédéric Peyrade
Journal:  Exp Hematol Oncol       Date:  2015-07-04

6.  Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.

Authors:  Andrzej Frankiewicz; Maria Saduś-Wojciechowska; Jacek Najda; Tomasz Czerw; Włodzimierz Mendrek; Małgorzata Sobczyk-Kruszelnicka; Katarzyna Soska; Małgorzata Ociepa; Jerzy Hołowiecki; Sebastian Giebel
Journal:  Contemp Oncol (Pozn)       Date:  2018-06-30

7.  BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.

Authors:  Ana Lucia Ron-Magaña; Omar Eduardo Fernandez-Vargas; Esperanza Barrera-Chairez; Carlos Silvestre Ron-Guerrero; Ana Jaqueline Bañuelos-Ávila
Journal:  Ann Transplant       Date:  2019-10-22       Impact factor: 1.530

8.  Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.

Authors:  Chen Tian; Yueyang Li; Su Liu; Zehui Chen; Yizhuo Zhang; Yong Yu; Hongliang Yang; Haifeng Zhao; Zhigang Zhao; Tian Yuan; Yafei Wang
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379

9.  [Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].

Authors:  L C An; Y H Liu; J Y Wang; J J Ma; J Q Xu; K M Li; R X Wei; J R Sui; X Y Feng; X Q Liu; L M Chen; X X Chu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

10.  Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Authors:  Maurizio Musso; Giuseppe Messina; Nicola Di Renzo; Paolo Di Carlo; Umberto Vitolo; Renato Scalone; Gianpaolo Marcacci; Potito R Scalzulli; Tiziana Moscato; Rossella Matera; Alessandra Crescimanno; Stella Santarone; Enrico Orciuolo; Anxur Merenda; Vincenzo Pavone; Domenico Pastore; Daniela Donnarumma; Angelo M Carella; Chiara Ciochetto; Nicola Cascavilla; Anna Mele; Francesco Lanza; Massimo Di Nicola; Erminio Bonizzoni; Antonello Pinto
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.